Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy
出版年份 2019 全文链接
标题
Gr-MDSC-linked asset as a potential immune biomarker in pretreated NSCLC receiving nivolumab as second-line therapy
作者
关键词
Lung cancer, Immunotherapy, Nivolumab, MDSC, PDL1
出版物
Clinical & Translational Oncology
Volume -, Issue -, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2019-06-28
DOI
10.1007/s12094-019-02166-z
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes
- (2019) Deborah B Doroshow et al. CLINICAL CANCER RESEARCH
- Tumor Mutation Burden—From Hopes to Doubts
- (2019) Alfredo Addeo et al. JAMA Oncology
- Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer
- (2019) Su-Myeong Park et al. ARCHIVES OF PHARMACAL RESEARCH
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression
- (2018) Heng Lin et al. JOURNAL OF CLINICAL INVESTIGATION
- Molecular Determinants of Response to Anti–Programmed Cell Death (PD)-1 and Anti–Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non–Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
- (2018) Hira Rizvi et al. JOURNAL OF CLINICAL ONCOLOGY
- Prognostic utility of baseline neutrophil-to-lymphocyte ratio in patients receiving immune checkpoint inhibitors: a review and meta-analysis
- (2018) Danielle Benedict Sacdalan et al. OncoTargets and Therapy
- Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy
- (2017) Nicole Glodde et al. IMMUNITY
- MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC
- (2017) M. Kowanetz et al. Journal of Thoracic Oncology
- PD-L1 IHC in NSCLC with a global and methodological perspective
- (2017) Erik Thunnissen et al. LUNG CANCER
- The immune contexture in cancer prognosis and treatment
- (2017) Wolf H. Fridman et al. Nature Reviews Clinical Oncology
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Baseline relative eosinophil count as a predictive biomarker for ipilimumab treatment in advanced melanoma
- (2017) Pier Francesco Ferrucci et al. Oncotarget
- PD-1 Pathway Inhibitors: Changing the Landscape of Cancer Immunotherapy
- (2017) Dawn E. Dolan et al. Cancer Control
- Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
- (2016) M. Sade-Feldman et al. CLINICAL CANCER RESEARCH
- Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells
- (2016) Olivier De Henau et al. NATURE
- The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
- (2015) Daniel Sanghoon Shin et al. CURRENT OPINION IN IMMUNOLOGY
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Cancer Genome Landscapes
- (2013) B. Vogelstein et al. SCIENCE
- Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-Smokers
- (2012) Ramaswamy Govindan et al. CELL
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started